Skip to main content

Pharvaris

DEUCRICTIBANT

Pharvaris is harnessing its established legacy in bradykinin B2 receptor science to advance investigational oral therapies for bradykinin-mediated angioedema.

Deucrictibant

Deucrictibant is an orally administered bradykinin B2 receptor antagonist in development for the prevention and treatment of bradykinin-mediated angioedema attacks. Deucrictibant utilizes the same mechanism of action as icatibant, current standard-of-care for the on-demand treatment of HAE attacks.

Mechanism of Action

Deucrictibant is a selective bradykinin B2 receptor antagonist that prevents the binding of bradykinin to the bradykinin B2 receptor, thereby blocking the activity of the main mediator responsible for AE-BK swelling.

Drug Properties

In addition to utilizing the clinically-proven mechanism of action of antagonism of the bradykinin B2 receptor, deucrictibant also offers:

Oral bioavailability

Throughout the years, researchers have attempted to develop a bradykinin B2 receptor antagonist that could be delivered orally. As a small molecule, deucrictibant has high oral bioavailability.

Selectivity

Deucrictibant is highly selective to the bradykinin B2 receptor, resulting in virtually no off-target activity on the bradykinin B1 receptor.

Potency

Deucrictibant is approximately 20-fold more potent than icatibant.

Two oral products with the same active ingredient, deucrictibant, are in development for the prevention and treatment of bradykinin-mediated angioedema attacks.

DEUCRICTIBANT

EXTENDED RELEASE (XR)

Sustained absorption

In studies, deucrictibant maintained sustained therapeutic exposure over 24 hours from day one, allowing for once-daily oral treatment to prevent HAE attacks*

  • Highly effective at preventing attacks*
  • Potential for rapid and durable protection
  • Well tolerated
  • Once-daily oral administration

Extended-Release (XR) Tablet

The tablet formulation maintains matrix stability through the acid stomach environment, then begins to degrade when the pH in the gut and colon increases. This delayed release of drug substance from the tablet formulation, combined with deucrictibant’s colonic absorption, allows for an optimized plasma exposure profile for prophylaxis.
Pharmacokinetics/Pharmacodynamics
Deucrictibant XR achieves therapeutic exposure in approximately 1.5 hours, maintains therapeutic exposure for over 24 hours, and reaches steady state in 2-3 days, supporting its development and, upon regulatory approval, potential future use as a daily prophylactic treatment.

IMMEDIATE RELEASE (IR)

Rapid absorption

In studies, deucrictibant rapidly reaches therapeutic exposure within 15-30 minutes, allowing for on-demand oral treatment of HAE attacks

  • Rapid onset of action
  • Potential for single-capsule resolution
  • Well tolerated
  • Oral administration

Immediate-Release (IR) Capsule

The capsule formulation rapidly dissolves in the stomach to enable rapid (within 15-30 minutes) plasma exposure.
Pharmacokinetics/Pharmacodynamics

Deucrictibant IR maintains plasma exposure for >8 hours, supporting its development and, upon regulatory approval, potential future use as an on-demand treatment.

*To be confirmed with clinical data from Phase 3 studies

Publications

Learn more about our scientific discoveries in our latest publications
EXPLORE PUBLICATIONS

Publications

Learn more about our scientific discoveries in our latest publications
EXPLORE PUBLICATIONS

References

Aygoren-Pursun E, et al. Lancet Hematol. 2026. | Bravo J, et al. Bradykinin Symposium. 2026. | Busse PJ, et al. N Engl J Med. 2020. | Cicardi M, et al. N Engl J Med. 2010. | FIRAZYR (icatibant) U.S. Prescribing Information. | Lesage A, et al. Front Pharmcol. 2020. | Lesage A. IDDST. 2024. | Lesage A, et al. Int Immunopharmacol. 2022. | Maurer M, et al. Clin Exp Allergy. 2022. | Maurer M, et al. Lancet Haematol. 2026. | Reshef A, et al. J Allergy Clin Immunol. 2024. | Riedl MA, et al. Clin Rev Allergy Immunol. 2026. | Smith TD and Riedl MA. Ann Allergy Asthma Immunol. 2024. | Zhang ZY, et al. AAAAI. 2026.